32 results about "FOOD EFFECT" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The present invention relates methods for treating thyroid cancer, renal cell carcinoma or hepatocellar carcinoma comprising orally administering to a patient in need of such therapy a therapeutic amount of cabozantinib lauryl sulfate salt, preferably in a capsule form. The method allows the administration of the therapeutic amount of cabozantinib lauryl sulfate salt in a fed state or a fasted state and the administration does not exhibit a food effect.

The present invention relates methods for treating thyroid cancer, renal cell carcinoma or hepatocellar carcinoma comprising orally administering to a patient in need of such therapy a therapeutic amount of cabozantinib lauryl sulfate salt, preferably in a capsule form. The method allows the administration of the therapeutic amount of cabozantinib lauryl sulfate salt in a fed state or a fasted state and the administration does not exhibit a food effect.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

A composition comprising neratinib, or a pharmaceutically acceptable salt thereof, and hydroxypropyl-β-cyclodextrin, a method for preparing same, and use thereof. Study results show that the composition can not only significantly improve the bioavailability of the active ingredient, but also eliminate food effects and adverse event diarrhea.

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and / or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

The present application relates to a lurasidone hydrochloride pharmaceutical composition and a preparation method thereof. The present application discloses a lurasidone hydrochloride pharmaceutical composition, which comprises lurasidone hydrochloride and a stabilizer, wherein the lurasidone hydrochloride is in nanoscale. The prepared lurasidone hydrochloride pharmaceutical composition can improve the solubility and bioavailability of the drug, and reduce the influence of food effect. The preparation method of the present application is simple in operation, low in production cost and easy to realize industrialized scale-up production.

This invention provides a nilotinib capsule with reduced food-related effects and its preparation method, addressing the shortcomings of existing products. It solves the problem that existing products require avoiding the influence of food. This invention innovatively improves the dissolution and release of the drug in media with different pH values ​​by adding a specific combination of acidic pH adjusters and solubilizers to the formulation. This innovative formulation adjustment solves the problem of food affecting the release and absorption of this product, and improves the time-limited nature of administration. Therefore, this invention has great application value and promising prospects for promotion.

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and / or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and / or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This invention discloses a briceceran sustained-release tablet and its preparation method, belonging to the field of pharmaceutical formulations. This invention aims to solve the problems of food effect, release instability, and processability issues associated with briceceran sustained-release tablets. Technical solution: A tablet-within-a-tablet structure is adopted, with the sustained-release core containing a composite hydroxypropyl methylcellulose (high / medium viscosity mixture) and micronized ethyl cellulose, and the immediate-release outer layer containing a disintegrant; the preparation includes ethanol granulation and compression steps. Technical effects: Achieves stable drug release over 24 hours, with a postprandial / fasting release difference of <3%, avoiding dose dumping, while improving flowability and hardness by 53%, suitable for industrial production.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The invention discloses a nilotinib sustained release tablet and a preparation method thereof, the nilotinib sustained release tablet comprises a bleaching assisting layer and a drug-containing sustained release layer, the bleaching assisting layer is prepared from a hydrophilic polymer with the viscosity of 2000 mpa.s-6000 mpa.s, a hydrophobic bleaching assisting agent, an adhesive and a lubricant; the drug-containing sustained-release layer is prepared from the following raw materials: an amorphous solid dispersion containing nilotinib or salt thereof, a hydrophilic polymer with the viscosity of 40 mpa.s-2000 mpa.s, a water-soluble filler, a flow aid and a lubricant. The nilotinib sustained-release tablet can effectively prolong the retention time of nilotinib in the stomach, slowly release the medicine in the stomach, improve the solubility and bioavailability of the medicine and reduce the overall dosage, so that the adverse reaction of the medicine is reduced, and meanwhile, on the basis of ensuring that the nilotinib sustained-release tablet is not affected by food effects, the nilotinib sustained-release tablet only needs to be orally taken once every day, and the curative effect of the nilotinib sustained-release tablet is greatly improved. The medicine taking compliance of a patient is improved by reducing the medicine taking times.

The present disclosure relates to dosage forms comprising bupropion hydrochloride, bupropion in the form of another salt or bupropion in the form of a free base; dextromethorphan hydrobromide, dextromethorphan in the form of another salt or dextromethorphan in the form of a free base; and a polymer. In some embodiments, the dosage form does not have significant dose dumping of bupropion in vitro in the presence of ethanol. In some embodiments, the dosage form does not have a food effect on bupropion or dextromethorphan when taken in a human subject with a high fat diet. Some embodiments include a method of treating a nervous system condition, such as depression (e.g., major depression, including refractory depression), agitation associated with Alzheimer's disease (or agitation associated with dementia of Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety), neuropathic pain, or peridiabetic neuropathic pain, it comprises administering to a person in need thereof a dosage form described herein.

A lurasidone hydrochloride formulation, comprising lurasidone hydrochloride and a carrier, wherein the carrier comprises: Soluplus, and at least one of HPMCAS HG and HPMCAS HF. The formulation can increase the dissolution rate and solubility of lurasidone hydrochloride and ensure increased dissolution of lurasidone hydrochloride in the small intestine, such that the bioavailability and in-vivo absorption of lurasidone hydrochloride is improved, reducing excessive medication restrictions, avoiding reduced or even ineffective therapeutic effects caused by improper medication, and thus ensuring normal exertion of the efficacy of the drug. Moreover, the lurasidone hydrochloride formulation can also weaken or eliminate the food effect, thereby facilitating greater flexibility and compliance in patient medication.

The present invention relates to a pharmaceutical composition comprising solid dispersion of amorphous abiraterone acetate and one or more pharmaceutically acceptable excipients, having improved solubility, stability, bioavailability, and no positive food effect. The present invention also relates to a method for its preparation, a dosage form comprising such compositions, and the use of the said composition or dosage form as a medicament for the treatment of prostate cancer.

A method of administering diazepam having a food effect is described.

The utility model discloses an oil splash prevention device for food processing, comprising: an oil pan, a splash prevention cover is arranged on the top of the oil pan, a filter basket is arranged in the oil pan, a stirring mechanism is arranged in the filter basket, the stirring mechanism comprises a shell, a first wedge block and two second wedge blocks are slidingly arranged in the shell, the second wedge block is fixedly connected in the shell by a first spring, and the inclined surface on the first wedge block is tightly attached to the inclined surfaces on the two second wedge blocks, and a marking ring is fixedly connected in the oil pan. The utility model drives the filter basket to move back and forth in the vertical direction through the stirring mechanism, so that the oil and water in the oil pan impact the food, so that the frying effect of the food is better, and the filter basket can also be clamped at the position of the marking ring through the second wedge block to complete the process of filtering the fried food in the filter basket, so that the edible oil in the oil pan is stabilized, and the situation of oil and water splashing out and scalding the skin when the food is taken out is avoided.

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and / or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The present invention relates to a stable pharmaceutical composition of abiraterone or pharmaceutically acceptable salt thereof. Specifically, it relates to a stable pharmaceutical composition comprising a nanosuspension of abiraterone or pharmaceutically acceptable salt thereof that reduces the dose, lessen the pill burden, enhance the bioavailability of abiraterone in fasting conditions and reduce the food effect as compared to commercial products. A method of preparation of the said composition is also disclosed. Additionally, the invention pertains to the methods of treating certain cancers in mammalian subjects using the said composition.

A lurasidone solid dispersion and a preparation method thereof. The solid dispersion includes a mixture of lurasidone, a pharmaceutical carrier and a plasticizer, in which the lurasidone is in a free base form. The lurasidone solid dispersion obtained by the preparation method has characteristics of high dissolution rate (over 30%) in partial neutral medium (such as pH 6.0), significantly increased bioavailability, and significantly reduced food effect, which overcomes the excessive medication limitation in the prior art, avoids the reduction or even inefficiency of the curative effect caused by improper medication of patients, ensures the normal exertion of the medication effect, thereby increases the flexibility and compliance of patients to take medicine.

Provided herein are amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate, and pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions can be orally administered to a patient in the fed or fasted state with a reduction or elimination of food effect. Preferably, there is no substantial difference in the pharmacokinetic parameters (e.g., C max , AUC 0‑t , and / or AUC 0‑无穷大 ) of nilotinib following oral administration of the pharmaceutical composition, whether the pharmaceutical composition is administered to the subject in the fed or fasted state.